Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 15

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 15
---
. Thus, even if we no
longer qualify as an emerging growth company, but remain a foreign private issuer, we will continue to be exempt from the more stringent
compensation disclosures required of companies that are neither an emerging growth company nor a foreign private issuer.

<div align='center'>4</div>

THE OFFERING

| Common shares currently issued and outstanding                 |     | 5,466,441 common shares                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Common Shares offered by the selling shareholders              |     | Up to 17,016,694 common shares consisting of (i) 16,970,241 common                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
 shares consisting of the Note Shares issued or issuable upon conversion of the Initial Promissory Notes to the CLA Investors who are named                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
 as selling shareholders in the registration statement to which this prospectus relates and (ii) 46,453 common shares that were issued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
 to certain selling shareholders as equity award grants outside of the Plan.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Common Shares to be issued and outstanding after this offering |     | 22,483,135 common shares, assuming conversion in full of the Notes Shares registered under                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
 the registration statement pursuant to which this prospectus relates.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Use of proceeds                                                |     | As of the date of this prospectus, we have received $0.5 million in gross proceeds from the issuance of the First Initial Promissory Notes. In addition, we will receive an additional $1.75 million in aggregate gross proceeds under the SPAs from sales of the Second Initial Promissory Notes on the date on which the registration statement pursuant to which this prospectus relates is declared effective by the SEC and we will receive an additional $6.75 million in aggregate gross proceeds under the SPAs from sales of additional Promissory Notes during each subsequent three month period commencing on the date that is three months after the Second Initial Closing. We will not receive any proceeds from the sale of the common shares by the selling shareholder. All net proceeds from the sale of the common shares covered by this prospectus will go to the selling shareholder. We intend to use the net proceeds from the issuance of the Promissory Notes for general corporate purposes, which may include operating expenses, research